Servier to Acquire Day One Biopharmaceuticals for $21.50/Share, Valuing Company at $2.5 Billion
DAWN has more than doubled off its 52-week low of $5.635.
Summary
Day One Biopharmaceuticals has agreed to be acquired by Servier Pharmaceuticals LLC for $21.50 per share in cash, valuing the company at approximately $2.5 billion, representing a significant premium for shareholders.
Key Events · M&A and Partnerships · DAWN
-
Definitive Merger Agreement
Day One Biopharmaceuticals, Inc. has entered into an Agreement and Plan of Merger with Servier Pharmaceuticals LLC and Servier Detroit Inc. (Merger Sub).
-
Acquisition Price and Valuation
Servier will acquire all outstanding shares of Day One common stock for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. This is a significant premium over the current stock price and the 52-week high.
-
Board Recommendation
Day One's Board of Directors has unanimously approved the merger and recommends that shareholders accept the tender offer and tender their shares.
-
Strategic Rationale
The acquisition aims to strengthen Servier's position in rare oncology and expand its pipeline, leveraging Day One's scientific expertise and lead program in pediatric low-grade glioma (OJEMDA).
Analysis · DAWN · Life Sciences
Day One Biopharmaceuticals has entered into a definitive agreement to be acquired by Servier Pharmaceuticals LLC for $21.50 per share in cash. This represents a substantial premium of approximately 68.6% over the current stock price and significantly above the company's 52-week high of $13.20, offering a strong exit for shareholders. The total equity value of approximately $2.5 billion nearly doubles the company's current market capitalization. This acquisition follows recent positive developments, including strong financial results and a positive EMA opinion for its lead drug OJEMDA, which likely enhanced its appeal as an acquisition target. The Board's unanimous recommendation to tender shares indicates strong internal support for the deal. The transaction is subject to customary closing conditions, including majority tender and U.S. antitrust clearance, and is expected to close in Q2 2026. A termination fee of $87.7 million is in place, providing a significant deterrent to competing offers.
At the time of this filing, DAWN was trading at $12.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.64 to $13.20. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.